News Search Results
Jun 13, 2025, 01:10 ET Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Jun 12, 2025, 21:00 ET Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA)
More news about: Innovent Biologics
Jun 12, 2025, 12:01 ET Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA). Additional information
More news about: Specialised Therapeutics
Jun 11, 2025, 07:46 ET Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
Hospital, as well as Chairman of the Chinese Society of Clinical Oncology (CSCO) Radiation Therapy Committee; and Dr. Tao Yong, Director of the Ophthalmology Department at Beijing Chao-yang Hospital, Capital Medical University and one of Beijing's Top Ten Outstanding
More news about: Ping An Healthcare and Technology Company Limited
Jun 11, 2025, 07:32 ET Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
Hospital, as well as Chairman of the Chinese Society of Clinical Oncology (CSCO) Radiation Therapy Committee; and Dr. Tao Yong, Director of the Ophthalmology Department at Beijing Chao-yang Hospital, Capital Medical University and one of Beijing's Top Ten Outstanding
More news about: Ping An Healthcare and Technology Company Limited
Jun 11, 2025, 07:00 ET Nanoscope Therapeutics to Showcase Vision-Restoring Gene Therapies at the 2025 BIO International Convention
while also sharing updates on key milestones achieved on the path to deliver a first-in-class therapy to patients with the highest unmet needs in ophthalmology.
More news about: Nanoscope Therapeutics
Jun 11, 2025, 04:08 ET EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio
causes progressive vision loss and blindnessFunding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areasSTOCKHOLM,
More news about: EQT
Jun 11, 2025, 03:00 ET SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
SB-007 in Stargardt disease Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other undisclosed therapeutic areasBARCELONA, Spain,
More news about: SpliceBio
Jun 10, 2025, 12:38 ET SIFI merges into Faes Farma to become its ophthalmic franchise and expand international access to its portfolio and pipeline
to offer one of the most comprehensive ophthalmology portfolios in the industry, with a complementary geographic presence. The integration of SIFI and Laboratorios Edol, a leading Portuguese pharmaceutical recently acquired by Faes Farma, positions ophthalmology as a pivotal area for the combined entity
More news about: SIFI S.p.A.
Jun 10, 2025, 12:10 ET ReFocus Eye Health Announces Strategic Partnership with Leading Retina Practice
ReFocus Eye Health, a management services organization ("MSO") supporting a premier network of comprehensive ophthalmology and retina practices, is proud to announce its partnership with Atlantic Retina Center, a distinguished retina practice operating across six locations
More news about: ReFocus Eye Health
Jun 10, 2025, 08:37 ET RADPAIR and Accessium Group Inc. Partner to Deliver Scalable, AI-Driven Radiology Support Across North America
Accessium Group is a trusted provider of IT solutions and healthcare consulting, specializing in radiology, cardiology, pathology, ophthalmology, dentistry, and pharmacy informatics, digital transformation, AI-powered diagnostics and workflow, as well as healthcare system interoperability.
More news about: RADPAIR
Jun 09, 2025, 14:10 ET 20/20NOW Advances Tele-Optometry with New VP of Professional Services Dr. Noelle Tchang OD and Spotlights Telehealth at Digital EyeCon
Miami, hosted by the Bascom Palmer Eye Institute in Coral Gables, Florida. The conference, themed "Pioneering Ophthalmology in the Virtual Realm," explored innovative models enhancing patient accessibility and transforming the healthcare experience. 20/20NOW's
More news about: 20/20NOW
Jun 09, 2025, 12:45 ET Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships
AffaMed's pipeline and global footprint through five major transactions in under a year. Minji brings deep experience in oncology, immunology, ophthalmology, CNS, cardiovascular, and digital therapeutics, and has led both in- and out-licensing from early discovery to late-stage clinical assets. She is
More news about: Formation Bio
Jun 09, 2025, 12:00 ET VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
potent dual JAK1/TYK2 inhibitor for the treatment of post-operative inflammation following cataract surgery. Most importantly, the Division of Ophthalmology (DO), Office of Specialty Medicine (OSM) at FDA agreed with VivaVision that its US phase 2 trial (NCT06164743) may serve as one of the two pivotal
More news about: VivaVision Biotech
Jun 09, 2025, 12:00 ET Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)
June 21, 2025, by retinal specialist Veeral Sheth, MD, Clinical Asst. Professor of Ophthalmology, University of Illinois, and an investigator in the study. The LOTUS study (Part 1) was an open-label,
More news about: Eluminex Biosciences Limited
Jun 09, 2025, 08:30 ET Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Jun 09, 2025, 07:00 ET Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
Pharmaceuticals Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which BYQLOVI was developed,
More news about: Formosa Pharmaceuticals Inc.
Jun 06, 2025, 02:00 ET HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals:
More news about: HTL Biotechnology
Jun 05, 2025, 18:00 ET ZEISS CLARUS 700 Receives NMPA Approval in China
[email protected] Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
More news about: Carl Zeiss Meditec AG
Jun 05, 2025, 18:00 ET ZEISS CLARUS 700 Receives NMPA Approval in China
[email protected] Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
More news about: Carl Zeiss Meditec AG
Jun 05, 2025, 10:00 ET Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 4 products have been approved and commercialized, 1 product filed for pre-NDA meeting, 2 products
More news about: Mabwell
Jun 05, 2025, 09:00 ET OpenEvidence and the JAMA Network sign strategic content agreement
Cardiology, JAMA Dermatology, JAMA Health Forum, JAMA Internal Medicine, JAMA Neurology, JAMA Oncology, JAMA Ophthalmology, JAMA Otolaryngology–Head & Neck Surgery, JAMA Pediatrics, JAMA Psychiatry, and JAMA Surgery — including full
More news about: OpenEvidence
Jun 05, 2025, 06:00 ET Navigate Patient Solutions Adds Vance Thompson, MD, David Cox, and Matthew P. Jensen to Medical Advisory Board
to empower ophthalmology practices through a unique solution that activates, educates, and motivates patients." Navigate Patient Solutions is building something extraordinary in ophthalmology—a comprehensive, forward-thinking patient engagement solution. We invite ophthalmology practices
More news about: Navigate Patient Solutions
Jun 04, 2025, 20:23 ET Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products
More news about: Innovent Biologics
Jun 04, 2025, 20:00 ET Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce
More news about: Innovent Biologics